Pharmaceutical and other life sciences companies find themselves in an
increasingly difficult IT environment. Not only do they face the same business
challenges found in any large enterprise, from newer federal regulatory
initiatives such as the Sarbanes-Oxley Act of 2002 to more general concerns
of network security, infrastructure efficiency, and protecting intellectual property
– they also face specific oversight by the U.S. Food and Drug Administration.